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Predictors of Radiation Failure After Treatment of In- 
Stent Restenosis With Gamma Vascular Brachytherapy: 
Pooled Analysis From GAMMA I, II, and SCRIPPS III 
Studies 
Thosaohol Limoiiankit. A. Abizaid, R. Mehran, A. A. Lansky, G. Dangas, N. Kipshidze, G. 
W. Stone, M. B. Collins, J. W. Moses, M. B. Leon, P. S. Teirstein, Cardiovascular 
Research Foundation, New York, New York, Lenox Hill Heart & Vascular Institute, New 
York, New York. 
Background: Vascular Brachytherapy (VBT) is the only current effective therapy for treat- 
ment of in-stant restenosis. Despite its success, there is a failure rate of 15-30% depend- 
ing on lesion/patient substrate. 
Methods: Using the combined GAMMA-I and II and SCRIPP-III database, we sought to 
identify predictors of radiation failure following gamma-VBT(Ir-192) for ISR. Radiation 
failure was defined as composite of death, target vessel revasculanzation (TVR), myo- 
cardial infarction, late thrombosis or total occlusion at 6 months follow-up. 
Results: A total of 727 consecutive patients who enrolled in the active treatment arm of 
the GAMMA-I and II and SCRIPP-III tdals had complete follow-up at 6-9 months. Univari- 
ate predictors of radiation failure are shown in the table. Most failures resulted in revas- 
culadzation (80%), while others had either death, MI, thrombosis, or total occlusion. 
By stepwise logistic regression analysis, only reference vessel size (OR=0.4, p=0.005), 
new stent implantation (OR=2.07, p---O.O01) were independent predictors of radiation fail- 
ure. 
Conclusion: Although VBT using Ir-192 source for treatment of ISR is extremely effective, 
it results in 19% failure rate. When treating ISR with VBT, new stent placement should be 
avoided. Other more effective therapies (drug-eluting stects) should be evaluated in 
high-risk patients (small vessels). 
Radiation Failure No Radiation Failure p-Value 
(n=142) (n=585) 
Age (years) 60.5 ± 13.7 62.8 ± 11.5 0.06 
Male Gender 75.2% 74.9% NS 
History of MI (%) 49.3% 38.2% 0.01 
Diabetes Mellitus (%) 29.6% 35.0% NS 
Prior PTCA > 4 times 7.9% 2.9% 0.01 
Ref. Vessel Diameter (mm) 3.1 ± 0.3 3.3 ± 1.5 0.04 
New Stent Implantation (%) 53.5% 38.5% 0.0012 
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832-2 Efficacy of Sr-90 Beta Radiation for the Treatment of In- 
Stent Restenoeis: 24-Month Clinical Outcomes From 
the STents And Radiation Therapy Trial (START) 
Warren K. Laskav, Mohan Suntharalingam, Jeffrey Popma, Richard Heuser, Barry 
Rutherford, Paul Teirstein, Alexandra Lansky, Richard Kuntz, Raoul Bonan, University of 
Maryland School of Medicine, Baltimore, Maryland. 
Background: The STents and Radiation Therapy Trial (START), the first and largest tri- 
ple-blind multi-center andomized trial investigating the use of Sr-90 beta radiation for the 
treatment of in-stent restenosis, demonstrated a 31% to 66% reduction in angiographic 
and clinical outcome parameters for those patients receiving radiation vs. placebo at a 9 
month eodpoint. The objective of this study is to report clinical outcomes of patients 
enrolled in this trial at the 24 month (2 year) endpoint. 
Methods: 476 patients were enrolled in the START trial. 244 patients received Sr-90 
beta radiation; 232 patients received placebo. There were no significant differences in 
baseline parameters between the two groups. 
Results: At 24 months, patients receiving Sr-90 demonstrated a 26% reduction in major 
adverse cardiac event (MACE) rates, defined by death, MI, emergent CABG and target 
vessel revascularization, compared to patients receiving placebo (31.1% vs. 41.8%; p = 
0.0156). Target vessel failure (TVF) was reduced by 26% (31.1% vs. 41.8%; p = 0.0156), 
target vessel revascularization (TVR) was reduced by 43% (27.5% vs. 39.2%; p = 
0.0064) and target lesion revascularization was reduced by 33% (23.4% vs. 35.8%; p = 
0.0030) in patients receiving Sr-90 vs. patients receiving placebo, respectively. One 
patient presented with late site thrombosis in the Sr-90 group (0.4%), which occurred at 
day 244; this was not statistically significant compared to placebo (0.4% vs 0.0%; p = 
0.329). There were no other reported late site thrombosis events identified at the 24- 
month time period. 
Conclusion: The early (8-month~ clinical benefits of Sr-90 for the treatment of in-stent 
restenosis are persistent at 24 months. No additional clinical sequelae occurred in 
patients receiving St-90. This data suggests that vascular brachytherapy using Sr-90 
beta radiation for the treatment of in stent restenosis is clinically effective and safe with 
no unexpected deleterious effects at 24 months. 
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832-3 Vascular Brachytherapy for Ostlal In-Stent Restenotic 
Lesions 
(~ostantino Q. CostantinL Alexandre J. Lansky, Roxana Mehran. G. S. MIntz, Kartik 
Desai, Kazuyuki Shirai, Horia Marginean, Gregg W. Stone, George Dangas. Martin B. 
Leon, Cardiovascular Research Foundation, New York Ci~ New York. 
Background: In-stent restenosis in the ostial location remains a disease with high recur- 
rence after percutaneous reintervention. The impact of vascular brachytherapy (VBT) on 
ostial lesion remains unknown. Methods: We evaluated the angiographic results of 133 
pts treated with ostial in-stent restenosis selected from a pooled database of 990 pts 
enrolled in VBT randomized trials. Independent angiogrephic analyses (QCA) were per- 
formed at baseline and follow-up in 45 Gamma, 27 Beta, and 61 placebo pts. Results: 
Baseline lesion characteristics are similar in all groups with ACC/AHA lesion complexity 
>B1 in 82% of lesions. Baseline compared to follow-up total occlusions were present in 
8.9% vs 4.4% of gamma. 0% vs 3.7% of Beta. and 3.3% vs 8.2% of placebo pts (p=NS 
for all compansons). By pairwise comparison differences in binary angiographic resteno- 
sis reached significance between gamma vs. placebo (p<0.0001) and beta vs. placebo 
(p<0.0001), however no difference was found between both radiation strategies 
(p=0.64). 
Conclusion: Conventional treatment of ostial in-stent restenosis is associated with is a 
malignant recurrence rate. VBT with either a Gamma or a Beta sources result in similar 
significant reductions in restenosis compared to placebo (up to 80%). In addition, among 
pts with treatment failures after VBT, lesions are significantly more focal compared to pla- 
cebo. The observed benefits of VBT do not occur at the expense of higher total ccclusion 
rates. 
QCA Gamma Beta Palcebo p Value 
Baseline Lesion 14.9±9.5 15.2±8.3 19.5±10.9 NS 
Length (mm) 
FU Lesion 7.1±3.8" 4.6±3.1" 16.8±12.2"* <0.001 
Length (mm) 
Reference 2.71 ±0.39 2.64±0.66 2.61 ±0.44 NS 
(ram) 
Final DS % 27±15 21±14 27±13 0.11 
FU DS % 37±22 33±24 62±20 <0.0001 
Late Loss (ram) 0.31±0.58 0.31±0.60 0.94±0.57 <0.001 
Restenosis 17 22 75 <0.0001 
*p=O.008 and **p=0.14 for baseline to FU comparison 
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832"4 Wrist 12 Versus Wrist Plus: Twelve Versus Six Months 
of Clopldogrel for Prevention of Late Total Occlusion 
After Gamma Radiation Therapy for In-Stent Restenosis 
Ron Waksman, Andrew E. Ajani, Dong-Hun Cha, Daniella Claus, Regina Deible, Ellen 
Pinnow, Hongsheng Wu, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Joseph 
Lindsay, Washington Hospital Center, Washington, Dist. of Columbia. 
Background: An extended duration of antiplatelet herapy (6 months) for patients (pts) 
treated with intracoronary radiation therapy (IRT) utilizing a gamma emitter for the pre- 
vention of recurrent in-stent restenosis (ISR) reduces late thrombosis (LT). The aim of 
this study is to determine whether additional Clopidogrel therapy (6 months), further 
reduces the rate of LT and late total occlusion (LTO). Methods: WRIST 12 (Washington 
Radiation for In-Stent restenosis Trial with 12 months of Clopidogrel) is a registry of 120 
pts with diffuse ISR in native coronaries and vein grafts with lesions <80 mm in length, 
treated with IRT (192-1r). Patients were discharged on 12 months of Clopidogrel (75 mg 
QD) and scheduled for angiographic follow-up at 15 months. The clinical events of this 
cohort were compared with 120 pts from the WRIST PLUS registry (6 months of Clopi- 
dogrel after IRT). Results: Radiation was delivered successfully to all pts. Cfopidogrel 
was tolerated well and there was no report of leukopenia. Baseline clinical and anglo- 
graphic characteristics were similar to the WRIST PLUS cohort. The clinical events in pts 
who had completed 12 months of Clopidogrel were lower than those treated with 6 
months (Table). Conclusion: Twelve months of Clopidogrel for pts with ISR treated with 
gamma radiation is well tolerated and is associated with a reduction in the late total 
occlusion and revascularization rates compared to 6 months of Clopidogrel. Complete 
analysis will be available at presentation. 
Event WRIST 12 WRIST PLUS P 
(N=75) (N=111) 
TLR, % 17 31 0.04 
TVR, % 20 35 0.03 
MACE, % 21 36 0.32 
Late Thrombosis, % 1 3 0.52 
Late Total 3 10 0.06 
Occlusion, % 
